Statin-Associated Liver Dysfunction and Muscle Injury: epidemiology, Mechanisms, and Management Strategies

Int J Gen Med. 2024 May 11:17:2055-2063. doi: 10.2147/IJGM.S460305. eCollection 2024.

Abstract

Surveillance of drug safety is an important aspect in the routine medical care. Adverse events caused by real-world drug utilization has become one of the leading causes of death and an urgent issue in the field of toxicology. Cardiovascular disease is now the leading cause of fatal diseases in most countries, especially in the elderly population who often suffer from multiple diseases and need long-term multidrug therapy. Among which, statins have been widely used to lower bad cholesterol and regress coronary plaque mainly in patients with hyperlipidemia and atherosclerotic cardiovascular diseases (ASCVD). Although the real-world benefits of statins are significant, different degrees and types of adverse drug reactions (ADR) such as liver dysfunction and muscle injury, have a great impact on the original treatment regimens as well as the quality of life. This review describes the epidemiology, mechanisms, early identification and post-intervention of statin-associated liver dysfunction and muscle injury based on the updated clinical evidence. It provides systematic and comprehensive guidance and necessary supplement for the clinical safety of statin use in cardiovascular diseases.

Keywords: cardiovascular diseases; countermeasures; liver dysfunction; muscle injury; statin.

Publication types

  • Review

Grants and funding

This work was supported by Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (No. 2023KY1075), Jiaxing Key Discipline of Medicine--Clinical Pharmacy (2023-ZC-008), Public Technology Application Research Program of Zhejiang Province of China (NO. LGD21H310003), Science and Technology Project of Jiaxing of China (NO. 2021AD10023), National Natural Science Foundation of China (Nos. 81974470, 82272004), Zhejiang Provincial Natural Science Foundation of China (Nos. LYY19H280006, LQ21H310004, LY18H180001, LGF22H180008), and Zhejiang Provincial Science Technology Projects of Traditional Chinese Medicine (Nos. 2021ZB174, 2021ZB301).